Suggestions
Dan Rose
Medtech CEO, Advisor and Board Member
Dan Rose is the Chief Executive Officer (CEO) of Endovascular Engineering, a company focused on advancing clot removal technologies for venous thromboembolism (VTE). He was appointed to this position on August 20, 2024, succeeding Mike Rosenthal, who remains as Chief Operating Officer and a board member of the company.123
Prior to joining Endovascular Engineering, Rose served as the CEO of LimFlow, a company dedicated to limb salvage for patients with chronic limb-threatening ischemia (CLTI). At LimFlow, he was instrumental in guiding the company through its acquisition by Inari Medical and played a key role in developing a therapy that received FDA approval and was published in the New England Journal of Medicine.123
Rose's career includes significant roles in various medical device companies. He was Vice President and General Manager for Europe at Direct Flow Medical and held leadership positions at Sequana Medical and Medtronic in Europe. He holds a BA and MA from the University of Virginia and an MBA from its Darden School of Business.1234
In his new role, Rose aims to lead Endovascular Engineering in establishing the Hēlo PE thrombectomy system as a preferred treatment option for pulmonary embolism, emphasizing the company's commitment to clinical innovation and patient care.123
